9075

## IN ASSEMBLY

February 6, 2024

Introduced by M. of A. SEPTIMO -- read once and referred to the Committee on Insurance

AN ACT to amend the insurance law, in relation to requiring health insurance policies to fully cover comprehensive genetic testing and FDA approved biomarker testing for ovarian and prostate cancers

The People of the State of New York, represented in Senate and Assembly, do enact as follows:

Section 1. This act shall be known and may be cited as the "Ana Lucia 1 2 act". 3 § 2. Paragraph 11-a of subsection (i) of section 3216 of the insurance 4 law is amended by adding a new subparagraph (C) to read as follows: 5 (C) (i) Such policy shall provide additional full coverage for compreб hensive genetic testing and FDA approved testing based on family or 7 person's history for prostatic and ovarian cancer when recommended by a 8 doctor, a board-certified geneticist or a board-certified genetic coun-9 selor. Such coverage shall also be provided after the patient's initial 10 diagnosis. Patients need to know if they carry the genetic or inheri-11 tance mutation, which can help to determine possible treatments. Genetic 12 screening shall be covered for prostate and ovarian cancer patients' family members. The genetic result shall not be used against family 13 14 members that carry the genetic or inheritance mutation for insurance coverage purposes. 15 16 (ii) All costs associated with such additional full coverage shall not 17 be subject to annual deductibles and coinsurance but shall be borne 18 solely by the insurer. § 3. Paragraph 11-a of subsection (1) of section 3221 of the insurance 19 20 law is amended by adding a new subparagraph (C) to read as follows: 21 (C)(i) Such policy shall provide additional full coverage for compre-22 hensive genetic testing and FDA approved testing based on family or 23 person's history for prostatic and ovarian cancer when recommended by a doctor, a board-certified geneticist or a board-certified genetic coun-24 25 selor. Such coverage shall also be provided after the patient's initial 26 diagnosis. Patients need to know if they carry the genetic or inheri-27 tance mutation, which can help to determine possible treatments. Genetic

EXPLANATION--Matter in <u>italics</u> (underscored) is new; matter in brackets [-] is old law to be omitted.

LBD00460-01-3

A. 9075

-	
1	screening shall be covered for prostate and ovarian cancer patients'
2	family members. The genetic result shall not be used against family
3	members that carry the genetic or inheritance mutation for insurance
4	coverage purposes.
5	(ii) All costs associated with such additional full coverage shall not
6	be subject to annual deductibles and coinsurance but shall be borne
7	solely by the insurer.
8	§ 4. Subsection (z-1) of section 4303 of the insurance law is amended
9	by adding a new paragraph 3 to read as follows:
10	(3)(A) Such policy shall provide additional full coverage for compre-
11	hensive genetic testing and FDA approved testing based on family or
12	person's history for prostatic and ovarian cancer when recommended by a
13	doctor, a board-certified geneticist or a board-certified genetic coun-
14	<u>selor.</u>
15	(B) All costs associated with such additional full coverage shall not
16	be subject to annual deductibles and coinsurance but shall be borne
17	solely by the insurer. Such coverage shall also be provided after the
18	patient's initial diagnosis. Patients need to know if they carry the
19	genetic or inheritance mutation, which can help to determine possible
20	treatments. Genetic screening shall be covered for prostate and ovarian
21	cancer patients' family members. The genetic result shall not be used
22	against family members that carry the genetic or inheritance mutation
23	for insurance coverage purposes.
24	§ 5. This act shall take effect on the sixtieth day after it shall
25	have become a law and shall apply to all policies, contracts and certif-
26	icates issued, renewed, modified, altered or amended on or after such

27 date.